- 2009.04.22
- National Cancer Center in Japan gains a regulatory approval of the clinical research for HSV-TK "haplo add-back" gene therapy in treatment of leukemia [New!]
- 2008.12.01
- Supply of RetroNectin® to UCLA for TCR-gene therapy clinical trials of advanced melanoma
- 2008.10.07
- Start of the HSV-TK Gene Therapy Clinical Trial for Relapsed Leukemia
- 2008.09.29
- Takara Bio Inc. to supply RetroNectin® to University of Washington School of Medicine for gene therapy targeting glioblastoma, a type of malignant brain tumors
- 2008.09.10
- Takara Bio Grants Promega Corporation a license for LA-PCR Technology
Copyright © 2009 TAKARA BIO INC. All rights reserved.